Abstract 1252P
Background
Although genomic profiling is commonly used to characterize tumors, clinical treatment successes are limited. For many tumors no actionable results are found. Furthermore it is often unknown if an identified genomic alteration affects cell functionality. By using the OncoSIGNal platform technology the actual tumor-driving signal transduction pathway (STP) activities can be quantified resulting in unique tumor profiling. Using healthy tissue as reference, high pathway activities can be determined in an individual patient giving guidance for personalized treatment. Recently we demonstrated for breast and ovarian tumors this approach leading to highly personalized actionable results, which can be used in the FINPROVE study. We further expanded the approach to other tumors. Here the results of STP profiling of skin tumors are presented.
Methods
Using the mRNA-based OncoSIGNal pathway activity profiling PCR test (InnoSIGN), STP activities of 7 pathways (AR, ER, PI3K, MAPK, HH, TGFβ and Notch) in 25 samples from healthy skin tissue, 35 primary melanoma, 39 metastatic melanoma and 18 basal cell carcinoma (BCC) were quantified and expressed on a scale from 0-100. Only samples with ≥ 50% epithelial cell content were included. High pathway activity in a tumor sample was concluded when its score was higher than the 95th percentile of reference skin STP activity.
Results
Different profiles of high pathway activity were found across skin tumor types: Table: 1252P
HH | MAPK | PI3K | TGFβ | |
BCC (n=18) | 94% | 44% | 22% | 11% |
Primary melanoma (n=35) | 14% | 6% | 51% | 6% |
Metastatic melanoma (n=39) | 18% | 15% | 38% | 5% |
Further, within the skin tumor types, patient specific STP profiles were observed.
Conclusions
Using the OncoSIGNal test, actionable STP profiles were determined in samples from melanoma and BCC patients, creating opportunity for personalized targeted treatment. The OncoSIGNal test will be employed in the FINPROVE trial to identify patient specific actionable targets in several tumor types using tissue specific references.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
InnoSIGN.
Funding
Has not received any funding.
Disclosure
D. Keizer, E. den Biezen, A. Van Brussel: Financial Interests, Institutional, Full or part-time Employment: InnoSIGN. E. Niemela, S. Karjalainen: Financial Interests, Institutional, Full or part-time Employment: Helsinki University Hospital. Y. Wesseling Rozendaal: Financial Interests, Personal and Institutional, Full or part-time Employment, Full Time Employee: InnoSIGN. M.V.J. Mustonen: Financial Interests, Institutional, Full or part-time Employment: FICAN South, Helsinki University Hospital. K. Peltola: Financial Interests, Institutional, Full or part-time Employment: Comprehensive Cancer Center.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14